Clinical trials
Juvenile Idiopathic Arthritis clinical trials
Below are recruiting juvenile idiopathic arthritis clinical trials, each written for real people, not researchers. We’re tracking 46 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07845942Recruiting
Donor stem cell transplant for stubborn systemic juvenile arthritis
This study tests a bone marrow transplant (using donor cells) to treat severe systemic juvenile idiopathic arthritis (sJIA) that has not responded to other treatments. The goal is to reset the immune system to stop the disease and its complications, like lung problems or recurrent macrophage activation syndrome.
Cincinnati, OhioAges Up to 35 years - NCT06560606Recruiting
Personalized medicine for childhood arthritis
This study creates a personalized medicine network to better understand and treat childhood arthritis. If you have JIA or unexplained joint inflammation, researchers will look at your biology to find the best treatment approach for you.
Calgary, AlbertaAges Up to 18 years - NCT07554495RecruitingPhase 3
Filgotinib for moderate to severe polyarticular juvenile arthritis
This trial tests filgotinib, a new medication that may help reduce joint swelling and pain in children and teens (ages 8–17) with polyarticular juvenile idiopathic arthritis—a type of childhood arthritis affecting multiple joints. You're eligible if your current arthritis medicines haven't worked well enough.
LeuvenAges 8–18 - NCT07517575RecruitingPhase 2
Olokizumab for Children with Juvenile Idiopathic Arthritis
This trial tests a new medicine called olokizumab in children and teenagers with juvenile idiopathic arthritis (JIA)—a condition where the immune system causes joint inflammation and pain. The study checks if this drug is safe and effective for children whose arthritis hasn't improved enough with standard treatments.
Kazan'Ages 2–17 - NCT07386587Enrolling by invitationPhase 3
Methotrexate plus etanercept for juvenile arthritis
This study compares methotrexate alone versus methotrexate combined with etanercept to see which works better for children with polyarticular juvenile idiopathic arthritis. The goal is to help children achieve low disease activity quickly.
Lahore, Punjab ProvinceAges 2–16 - NCT06874608Recruiting
Does an exclusion diet help juvenile arthritis?
This study tests if removing certain foods can improve arthritis symptoms in children aged 6 to 17. It may be an option if current medicines are not working well or if you want to explore dietary changes.
FlorenceAges 6–18 - NCT06653634RecruitingPhase 4
Optimizing treatment for kids with JIA in remission
This trial tests whether children with juvenile idiopathic arthritis (JIA) who have been doing well for over a year can safely reduce their medications. The goal is to find the best way to keep arthritis under control while avoiding unnecessary treatments.
BergenAges 2–17 - NCT07234747Recruiting
Core stability: exergaming vs. standard exercises for kids with JIA
This study compares two types of core-strengthening exercises for children with juvenile idiopathic arthritis (JIA). One group does standard core-stability exercises, and the other plays active video games (exergaming) that work the same muscles. The goal is to see which approach works better and is more fun for kids.
Istanbul, BuyukcekmeceAges 8–12 - NCT07217782Recruiting
Pain in Juvenile Arthritis Study
This study looks at pain in kids with juvenile arthritis compared to healthy kids. It may help researchers understand pain better and improve future treatments.
St Louis, MissouriAges 9–17 - NCT06806774Recruiting
Daily living test for children with juvenile arthritis
This study tests whether a simple daily activities test works well for children and teens with juvenile idiopathic arthritis. It may help doctors better understand how the condition affects everyday tasks.
AnkaraAges 8–18 - NCT07184450RecruitingPhase 1
CAR-T cell therapy for children with hard-to-treat rheumatic diseases
This trial tests a new treatment using your child's own immune cells, modified to target B cells and fight severe rheumatic diseases like juvenile dermatomyositis, arthritis, scleroderma, or Sjogren's syndrome. It's for children who haven't improved with standard treatments.
Hangzhou, ZhejiangAges 5 years+ - NCT07087912RecruitingPhase 4
Dengue vaccine safety in people with autoimmune rheumatic diseases
This study tests the safety and immune response of a dengue vaccine in people aged 12–59 with stable autoimmune rheumatic diseases (like rheumatoid arthritis or lupus) who are on low-dose or no immune-suppressing medications. It also includes healthy volunteers for comparison.
São Paulo, São PauloAges 12–59 - NCT07000916Recruiting
Follow-up study for new arthritis in kids and young adults
This study follows children and young adults newly diagnosed with certain types of arthritis or related conditions to learn more about their health over time. It may help doctors better understand how these diseases progress and how treatments work.
BrusselsAges 2–50 - NCT03245801Recruiting
Juvenile arthritis registry for newly diagnosed children
This study collects information about children with juvenile idiopathic arthritis (JIA) soon after diagnosis. The information helps researchers understand how the condition and treatments change over time, and it may guide future care.
Calgary, AlbertaAges Up to 18 years - NCT06718569Recruiting
Pain in Inflammatory Joint Diseases
This study looks at pain in people with inflammatory joint diseases. It aims to understand how pain changes when you start or switch to a newer type of arthritis medication.
OsloAges 18 years+ - NCT06668181RecruitingPhase 3
Study of bimekizumab for kids with certain types of juvenile arthritis
This trial tests a drug called bimekizumab in children and teens with specific types of juvenile arthritis (enthesitis-related arthritis or psoriatic arthritis). It aims to see how the drug works in the body and if it's safe. This may help those who haven't gotten enough relief from standard anti-inflammatory medicines.
CalgaryAges 2–18 - NCT06654882RecruitingPhase 3
Comparing next treatments for juvenile arthritis after a first biologic
This study tests different arthritis medications given in sequence for children and young adults with polyarticular JIA who did not get enough relief from a first TNF inhibitor. It aims to find which next treatment works best and is safe.
San Francisco, CaliforniaAges 2–21 - NCT06474546Recruiting
Diet intervention feasibility study for juvenile arthritis
This trial tests whether a special diet can help children and teens with juvenile arthritis. If you join, you will follow the diet and provide stool samples so the researchers can see how it affects your gut and arthritis.
Winnipeg, ManitobaAges 8–18 - NCT05534347Recruiting
Blood marker study in teens with juvenile arthritis
This study looks at blood (and related) markers that may reflect inflammation in people with juvenile idiopathic arthritis. It may help doctors better understand disease activity and guide future care for patients who are able to join.
Paris, IDFAges 16 years+ - NCT05925452Recruiting
Genalumab for children with active systemic juvenile arthritis
This trial studies whether a medicine called genalumab can reduce inflammation and improve symptoms in children with active systemic juvenile idiopathic arthritis (sJIA). It also checks how safe the treatment is, including possible side effects.
Beijing, BenjingAges 2–17 - NCT05754710Recruiting
Kids taking Xeljanz for juvenile arthritis study
This study is collecting real-world information about how Xeljanz (tofacitinib) is used and how well it works in children with juvenile idiopathic arthritis. It may help improve how the medicine is used safely in everyday care.
SeoulAges 2–17 - NCT05609630RecruitingPhase 3
Testing two medicines for active systemic juvenile arthritis
This Phase 3 trial studies how well upadacitinib (a pill) and tocilizumab (a shot/IV medicine) improve symptoms and inflammation in children with active systemic juvenile idiopathic arthritis (sJIA). It also looks at side effects and how these medicines move through the body.
Phoenix, ArizonaAges 1–17 - NCT01962415RecruitingPhase 2
Reduced-intensity stem cell transplant for non-cancer disorders
This trial tests whether a gentler (reduced-intensity) conditioning treatment before a stem cell transplant works for non-cancer diseases. It uses specific donor stem cell matches and checks heart, lung, liver, and kidney function to help lower transplant stress while still aiming for benefit.
Pittsburgh, PennsylvaniaAges 2 months–55 years - NCT03773965RecruitingPhase 3
Baricitinib study for kids with juvenile arthritis
This study tests baricitinib, a medicine, in children and teens with juvenile idiopathic arthritis. It includes only families who already took baricitinib in an earlier study and did not stop it permanently or develop an allergy.
RosarioAges 1–18
Hear when a new Juvenile Idiopathic Arthritis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for juvenile idiopathic arthritis?
- Yes. Clin2 currently lists 46 recruiting juvenile idiopathic arthritis studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a juvenile idiopathic arthritis trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a juvenile idiopathic arthritis trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.